Rai Vandana, Yadav Upendra, Kumar Pradeep
Human Molecular Genetics Laboratory, Department of Biotechnology, VBS Purvanchal University, Jaunpur-222 003, UP, India. Email:
Asian Pac J Cancer Prev. 2017 May 1;18(5):1243-1250. doi: 10.22034/APJCP.2017.18.5.1243.
Background: Catechol-O-methyltransferase (COMT) is an important estrogen-metabolizing enzyme. Numerous case-control studies have evaluated the role COMT Val 158Met (rs4680;472G->A) polymorphism in the risk of breast cancer and provided inconclusive results, hence present meta-analysis was designed to get a more reliable assessment in Asian population. Methods: A total of 26 articles were identified through a search of four electronic databases- PubMed, Google Scholar, Science Direct and Springer link, up to March, 2016. Pooled odds ratios (ORs) with 95% con¬fidence intervals (CIs) were used as association measure to find out relationship between COMT Val158Metpolymorphism and the risk of breast cancer. We also assessed between study heterogeneity and publication bias. All statistical analyses were done by Open Meta-Analyst. Results: Twenty six case-control studies involving 5,971 breast cancer patients and 7,253 controls were included in the present meta-analysis. The results showed that the COMT Val158Met polymorphism was significantly associated with breast cancer risk except heterozygote model(allele contrast odds ratio (ORAvsG)= 1.13, 95%CI=1.02-1.24,p=0.01; heterozygote/co-dominant ORGAvsGG= 1.03, 95%CI=0.96-1.11,p=0.34; homozygote ORAAvsGG= 1.38, 95%CI= 1.08-1.76,p=0.009; dominant model ORAA+GAvsGG= 1.08, 95%CI=1.01-1.16,p=0.02; and recessive model ORAAvsGA+GG= 1.35, 95%CI=1.07-1.71,p=0.01). In addition, we also performed subgroup analysis based on source of controls and menopausal state of patients. Conclusions: In conclusion, the COMT Val158Met polymorphism was related to increased breast cancer susceptibility in the Asian population.
儿茶酚-O-甲基转移酶（COMT）是一种重要的雌激素代谢酶。众多病例对照研究评估了COMT Val 158Met（rs4680；472G→A）多态性在乳腺癌风险中的作用，但结果尚无定论，因此本荟萃分析旨在对亚洲人群进行更可靠的评估。方法：通过检索四个电子数据库——PubMed、谷歌学术、Science Direct和Springer link，截至2016年3月，共识别出26篇文章。采用合并比值比（OR）及95%置信区间（CI）作为关联度量，以探究COMT Val158Met多态性与乳腺癌风险之间的关系。我们还评估了研究间的异质性和发表偏倚。所有统计分析均通过Open Meta-Analyst完成。结果：本荟萃分析纳入了26项病例对照研究，涉及5971例乳腺癌患者和7253例对照。结果显示，除杂合子模型外，COMT Val158Met多态性与乳腺癌风险显著相关（等位基因对比比值比（ORA vs G）=1.13，95%CI=1.02 - 1.24，p = 0.01；杂合子/共显性OR GA vs GG = 1.03，95%CI = 0.96 - 1.11，p = 0.34；纯合子OR AA vs GG = 1.38，95%CI = 1.08 - 1.76，p = 0.009；显性模型OR AA + GA vs GG = 1.08，95%CI = 1.01 - 1.16，p = 0.02；隐性模型OR AA vs GA + GG = 1.35，95%CI = 1.07 - 1.71，p = 0.01）。此外，我们还根据对照来源和患者绝经状态进行了亚组分析。结论：总之，COMT Val158Met多态性与亚洲人群乳腺癌易感性增加有关。
